Critical reappraisal of intravenous metoclopramide in migraine attack: a systematic review and meta-analysis

Eken, Cenker

doi:10.1016/j.ajem.2014.11.013

Cited by 32 publications

(25 citation statements)

References 13 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 Most of the trials were performed with 10 mg of metoclopramide, which was reported to be an adequate dosing protocol for migraines. [6][7][8][9][11][12][13] Overall, our findings suggest that no difference was found between 10 mg intravenous metoclopramide and placebo regarding efficacy and safety in patients with acute migraines. A blinding protocol, intention-totreat analysis, and allocation concealment were not established or not elaborated in most of the trials.…”

Section: Con Clus Ionmentioning

confidence: 55%

“…5,11 Therefore, we aimed to perform a restricted search strategy to clarify the exact effect size of metoclopramide treatment in migraine cases. However, recent meta-analyses and systematic reviews have argued that the heterogeneity of studies for combination treatment prevented statistical pooling of the results.…”

Section: Discussionmentioning

confidence: 99%

“…4 Among these, metoclopramide is a well-known dopamine receptor antagonist with antiemetic properties and is widely used in EDs in the acute treatment of migraines. 5,10,11 Although previous randomized trials have mainly favored the use of this medication in an acute setting, 6,9,12 other studies were not compatible with this. [6][7][8][9] The use of metoclopramide in migraine treatment has been handled previously in several systematic reviews and meta-analyses.…”

Section: Importancementioning

confidence: 99%

See 2 more Smart Citations

Intravenous metoclopramide in the treatment of acute migraines: A randomized, placebo-controlled trial

et al. 2019

View full text Add to dashboard Cite

Objectives:The present study aimed to evaluate the efficacy and safety of intravenous metoclopramide for acute migraine treatment. Materials and methods:A double-blind, randomized, parallel-group, placebo-controlled trial was carried out in an academic emergency department. After the patients were assessed for eligibility via the International Headache Society criteria for migraines, they were randomized into 10 mg intravenous metoclopramide and normal saline groups. The headache intensity was evaluated using an 11-point numeric rating scale (NRS) score. The primary outcome measure was determined as the median between-group change in the score at the 30th minute. The secondary outcome measures were rescue medication needs, adverse events, and emergency department (ED) revisits after discharge. Results: A total of 148 patients were randomized into two equal groups with similar baseline characteristics, including the baseline NRS scores (8 points). The median reduction in the NRS scores at the 30th minute was 4 [interquartile range (IQR): 2-6)] in the metoclopramide group and 3 (IQR: 1-4) in the normal saline group [median difference: −1.0, 95% confidence interval (CI): −2.1 to 0.1]. No serious adverse events were observed, and the rescue medication needs were similar in both groups. Conclusion: No difference was found between intravenous metoclopramide and placebo regarding efficacy and safety in patients with acute migraines. K E Y W O R D S emergency department (MeSH Database), headache, metoclopramide, migraine How to cite this article: Doğan NÖ, Pekdemir M, Yılmaz S, et al. Intravenous metoclopramide in the treatment of acute migraines: A randomized, placebo-controlled trial.

show abstract

Section: Con Clus Ionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Section: Importancementioning

confidence: 99%

See 1 more Smart Citation

Intravenous metoclopramide in the treatment of acute migraines: A randomized, placebo-controlled trial

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Their use is based on criteria that have no empirical support (Valentine and Cooper, 2008). For example, some authors opt to use individual components (Field et al, 2014; Eken, 2015). Other authors apply scales that provide a global value, even when they are strongly criticized for the lack of a bias estimation (Crowe and Sheppard, 2011).…”

Section: Introductionmentioning

confidence: 99%

The Development of a Checklist to Enhance Methodological Quality in Intervention Programs

2016

View full text Add to dashboard Cite

The methodological quality of primary studies is an important issue when performing meta-analyses or systematic reviews. Nevertheless, there are no clear criteria for how methodological quality should be analyzed. Controversies emerge when considering the various theoretical and empirical definitions, especially in relation to three interrelated problems: the lack of representativeness, utility, and feasibility. In this article, we (a) systematize and summarize the available literature about methodological quality in primary studies; (b) propose a specific, parsimonious, 12-items checklist to empirically define the methodological quality of primary studies based on a content validity study; and (c) present an inter-coder reliability study for the resulting 12-items. This paper provides a precise and rigorous description of the development of this checklist, highlighting the clearly specified criteria for the inclusion of items and a substantial inter-coder agreement in the different items. Rather than simply proposing another checklist, however, it then argues that the list constitutes an assessment tool with respect to the representativeness, utility, and feasibility of the most frequent methodological quality items in the literature, one that provides practitioners and researchers with clear criteria for choosing items that may be adequate to their needs. We propose individual methodological features as indicators of quality, arguing that these need to be taken into account when designing, implementing, or evaluating an intervention program. This enhances methodological quality of intervention programs and fosters the cumulative knowledge based on meta-analyses of these interventions. Future development of the checklist is discussed.

show abstract

“…In clinical practice, metoclopramide has higher efficacy intravenously (6). In a metaanalysis performed with phase IV studies, sumatriptan and ketorolac were not found superior to iv metoclopramide in complete pain relief and rescue drug needs (7). Though metoclopramide provides an effective and safe treatment that is widely used to abort migraine attacks (6), its mechanisms of action are still unclear since very limited experimental studies are available.…”

Section: Introductionmentioning

confidence: 99%

Metoclopramide inhibits trigeminovascular activation:evidence for effective acute attack treatment in migraine

et al. 2017

View full text Add to dashboard Cite

Background/aim: Metoclopramide is an effective and commonly used medication in acute migraine treatment but an experimental evidence base is lacking. We aimed to investigate the antimigraine effect of metoclopramide in a migraine model and whether the analgesic effect of metoclopramide was likely to be D 2 receptor-mediated.Materials and methods: Cortical spreading depression (CSD) was used to model migraine in adult male Wistar rats. Five CSDs were induced by pinprick. Metoclopramide (two different doses), raclopride, or 0.9% saline were administered 30 min before CSD induction. Two hours after the experiments, brain tissues were examined for c-fos activation. Results:In metoclopramide groups brain stem c-fos expression was significantly lower than in the CSD side of the saline group (P = 0.002). In the raclopride group, ipsilateral brain stem c-fos expression was also lower than in the saline group (P = 0.002). No difference in c-fos expression in the ipsilateral trigeminal nucleus caudalis between the raclopride and metoclopramide groups was observed (P > 0.05). Conclusion:Metoclopramide is shown to suppress trigeminovascular activation for the first time, providing an experimental basis for its role in migraine. The analgesic effect of metoclopramide is likely to be mediated by D 2 receptors since raclopride, a selective D 2 receptor antagonist, suppresses trigeminovascular activation similarly.

show abstract

Critical reappraisal of intravenous metoclopramide in migraine attack: a systematic review and meta-analysis

Cited by 32 publications

References 13 publications

Intravenous metoclopramide in the treatment of acute migraines: A randomized, placebo-controlled trial

Intravenous metoclopramide in the treatment of acute migraines: A randomized, placebo-controlled trial

The Development of a Checklist to Enhance Methodological Quality in Intervention Programs

Metoclopramide inhibits trigeminovascular activation:evidence for effective acute attack treatment in migraine

Contact Info

Product

Resources

About